Abstract
Management of febrile neutropenia (FN) is an integral part of supportive care for patients undergoing cancer treatment. The NCCN Guidelines for Hematopoietic Growth Factors provide suggestions for appropriate evaluation, risk determination, prophylaxis, and management of FN. These NCCN Guidelines are intended to guide clinicians in the appropriate use of growth factors for select patients undergoing treatment of nonmyeloid malignancies. These NCCN Guidelines Insights highlight important updates to the NCCN Guidelines regarding the incorporation of newly FDA-approved granulocyte-colony stimulating factor biosimilars for the prevention and treatment of FN.
MeSH terms
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Biosimilar Pharmaceuticals / economics
-
Biosimilar Pharmaceuticals / standards
-
Biosimilar Pharmaceuticals / therapeutic use*
-
Chemotherapy-Induced Febrile Neutropenia / drug therapy*
-
Chemotherapy-Induced Febrile Neutropenia / etiology
-
Drug Approval
-
Drug Costs
-
Education, Medical, Continuing
-
Hematopoietic Cell Growth Factors / economics
-
Hematopoietic Cell Growth Factors / standards
-
Hematopoietic Cell Growth Factors / therapeutic use*
-
Humans
-
Medical Oncology / education
-
Medical Oncology / standards
-
Neoplasms / blood
-
Neoplasms / drug therapy*
-
Oncologists / education
-
Organizations, Nonprofit / standards
-
Practice Guidelines as Topic*
-
Risk Factors
-
United States
-
United States Food and Drug Administration / legislation & jurisprudence
Substances
-
Biosimilar Pharmaceuticals
-
Hematopoietic Cell Growth Factors